80, 84 Sloan, T
Key points GLP-1 is a hormone that increases insulin release and prevents the release of too much glucagon, helping manage blood glucose levels in individuals with type 2 diabetes GLP-1 receptor agonists, such as liraglutide and semaglutide, effectively reduce blood glucose levels Semaglutide is more effective than liraglutide at reducing blood sugar levels Tirzepatide is a newer GLP-1 receptor agonist that also mimics the actions of another hormone called GIP, which can also reduce blood sugar levels A randomised controlled trial showed that tirzepatide led to more significant blood sugar reductions than semaglutide across three doses Tirzepatide may be more effective than semaglutide at higher doses, but this needs further investigation Liraglutide and semaglutide are available in the UK and the US, while tirzepatide is only available in the US but is likely to be approved in the UK soon
doi: 10.1177/1559827617722137 Retrieved from
Molecular pathways: targeting IDO1 and other tryptophan dioxygenases for Cancer immunotherapy
The members of the ABCC family are ATP-dependent efflux pumps, belonging to the ABC family of transport proteins, and they are also involved in resistance against anticancer drugs
Zeller JM, Henig I, Radwanska E, Dmowski WP: Enhancement of human monocyte and peritoneal macrophage chemiluminescence activities in women with endometriosis
